{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025278","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.279855+00:00","generated_at":"2026-06-22T18:21:29.280862+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF","bullets":["First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.","Study evaluating safety, tolerability, and PK in healthy volunteers; results expected in 2023.","IPF affects over 3 million patients worldwide; median survival 3-5 years from diagnosis.","PRS-220 is the second inhaled respiratory program Pieris has brought into the clinic.","CEO Stephen Yoder highlights potential for meaningful improvement in quality of life for IPF patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025278","json":"https://secwatch.observer/filing/0001437749-22-025278.json","markdown":"https://secwatch.observer/filing/0001437749-22-025278.md","text":"https://secwatch.observer/filing/0001437749-22-025278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/0001437749-22-025278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774922025278/pirs20221031b_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:21:29.280862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}